Pancreatic and Hepatic Steatosis in Women with Type 2 Diabetes after Pancreatitis: A Retrospective Cross-Sectional Study

OBJECTIVE: This study aimed to compare the incidence of pancreatic steatosis and hepatic steatosis between patients with/without diabetes suffering from pancreatitis. MATERIALS AND METHODS: 120 patients between the ages of 18 and 65 years who were hospitalized with pancreatitis were included in the study. The patients were divided into 2 groups: patients with diabetes with pancreatitis (n = 60, Group 1) and patients without diabetes with pancreatitis (n = 60, Group 2). Biochemical blood tests of the patients were analyzed. HU attenuation measurement results on pancreatic abdominal computed tomography (CT) were evaluated retrospectively. The pancreatic-hepatic steatosis status of the patients was recorded. All parameters were compared between the 2 groups. RESULTS: The study was conducted on a total of 120 female patients with pancreatitis. The average age of the patients was 52.3 years, the mean body mass index (BMI) was 27.3 kg/m2, the mean HbA1c was 7.4%, and the mean diabetes duration was 4.6 years. The incidence of pancreatic steatosis was found to be statistically significantly higher in Group 1 (p < 0.05). While 35.0% (n = 21) of pancreatic steatosis was detected in Group 2, 56.7% (n = 34) of Group 1 were found to have pancreatic steatosis. The mean Hounsfield unit (HU) attenuation differences in the pancreas, corpus, and tail in Group 1 and Group 2 were determined to be statistically significant. (p = 0.030, 0.25, and 0.18, respectively). In the correlation analysis, a statistically significant and weak relationship was found between HbA1c and tail and pancreas/spleen values (p < 0.05). It was determined that there was a statistically significant and weak relationship between glucose and corpus, tail, pancreas, and pancreas/spleen values (p < 0.05). CONCLUSIONS: In our study, pancreatic steatosis was found to be more common in Group 1. However, no significant difference was detected between Group 1 and Group 2 in terms of hepatosteatosis.